Kornelia Kotseva1, Dirk De Bacquer2, Catriona Jennings3, Viveca Gyberg4, Guy De Backer2, Lars Rydén4, Philippe Amouyel5, Jan Bruthans6, Renata Cifkova6, Jaap W Deckers7, Johan De Sutter8, Zlatko Fraz9, Ian Graham10, Irena Keber9, Seppo Lehto11, David Moore10, Andrzej Pajak12, David Wood3. 1. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: k.kotseva@imperial.ac.uk. 2. Department of Public Health, University Hospital Ghent, Ghent, Belgium. 3. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 4. Cardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. 5. Institut Pasteur de Lille, Inserm U744, Université Lille Nord de France, Lille, France. 6. First Medical Faculty Charles University and Thomayer Hospital, Centre for Cardiovascular Prevention, Prague, Czech Republic. 7. Department of Cardiology, Thoraxcenter, Rotterdam, the Netherlands. 8. AZ Maria Middelares, Ghent, Belgium. 9. University Medical Centre, Ljubljana, Slovenia. 10. The Adelaide and Meath Hospital, Tallaght, Ireland. 11. Kuopio University Hospital, Kuopio, Finland. 12. Zakład Epidemiologii i Badań Popupulacyjnych CMUJ, Cracow, Poland.
Abstract
BACKGROUND: The EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) cross-sectional surveys describe time trends in lifestyle and risk factor control among coronary patients between 1999 and 2013 in Belgium, Czech Republic, Finland, France, Ireland, the Netherlands, Poland, Slovenia, and the United Kingdom as part of the EuroObservational Research Programme under the auspices of European Society of Cardiology. OBJECTIVES: This study sought to describe time trends in lifestyle, risk factor control, and the use of evidence-based medication in coronary patients across Europe. METHODS: The EUROASPIRE II (1999 to 2000), III (2006 to 2007), and IV (2012 to 13) surveys were conducted in the same geographical areas and selected hospitals in each country. Consecutive patients (≤70 years) after coronary artery bypass graft, percutaneous coronary intervention, or an acute coronary syndrome identified from hospital records were interviewed and examined ≥6 months later with standardized methods. RESULTS: Of 12,775 identified coronary patients, 8,456 (66.2%) were interviewed. Proportion of current smokers was similar across the 3 surveys. Prevalence of obesity increased by 7%. The prevalence of raised blood pressure (≥140/90 mm Hg or ≥140/80 mm Hg with diabetes) dropped by 8% from EUROASPIRE III to IV, and therapeutic control of blood pressure improved with 55% of patients below target in IV. The prevalence of low-density lipoprotein cholesterol ≥2.5 mmol/l decreased by 44%. In EUROASPIRE IV, 75% were above the target low-density lipoprotein cholesterol <1.8 mmol/l. The prevalence of self-reported diabetes increased by 9%. The use of evidence-based medications increased between the EUROASPIRE II and III surveys, but did not change between the III and IV surveys. CONCLUSIONS: Lifestyle habits have deteriorated over time with increases in obesity, central obesity, and diabetes and stagnating rates of persistent smoking. Although blood pressure and lipid management improved, they are still not optimally controlled and the use of evidence-based medications appears to have stalled apart from the increased use of high-intensity statins. These results underline the importance of offering coronary patients access to modern preventive cardiology programs.
BACKGROUND: The EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) cross-sectional surveys describe time trends in lifestyle and risk factor control among coronary patients between 1999 and 2013 in Belgium, Czech Republic, Finland, France, Ireland, the Netherlands, Poland, Slovenia, and the United Kingdom as part of the EuroObservational Research Programme under the auspices of European Society of Cardiology. OBJECTIVES: This study sought to describe time trends in lifestyle, risk factor control, and the use of evidence-based medication in coronary patients across Europe. METHODS: The EUROASPIRE II (1999 to 2000), III (2006 to 2007), and IV (2012 to 13) surveys were conducted in the same geographical areas and selected hospitals in each country. Consecutive patients (≤70 years) after coronary artery bypass graft, percutaneous coronary intervention, or an acute coronary syndrome identified from hospital records were interviewed and examined ≥6 months later with standardized methods. RESULTS: Of 12,775 identified coronary patients, 8,456 (66.2%) were interviewed. Proportion of current smokers was similar across the 3 surveys. Prevalence of obesity increased by 7%. The prevalence of raised blood pressure (≥140/90 mm Hg or ≥140/80 mm Hg with diabetes) dropped by 8% from EUROASPIRE III to IV, and therapeutic control of blood pressure improved with 55% of patients below target in IV. The prevalence of low-density lipoprotein cholesterol ≥2.5 mmol/l decreased by 44%. In EUROASPIRE IV, 75% were above the target low-density lipoprotein cholesterol <1.8 mmol/l. The prevalence of self-reported diabetes increased by 9%. The use of evidence-based medications increased between the EUROASPIRE II and III surveys, but did not change between the III and IV surveys. CONCLUSIONS: Lifestyle habits have deteriorated over time with increases in obesity, central obesity, and diabetes and stagnating rates of persistent smoking. Although blood pressure and lipid management improved, they are still not optimally controlled and the use of evidence-based medications appears to have stalled apart from the increased use of high-intensity statins. These results underline the importance of offering coronary patients access to modern preventive cardiology programs.
Authors: Piotr Jankowski; Dariusz A Kosior; Paweł Sowa; Karolina Szóstak-Janiak; Paweł Kozieł; Agnieszka Krzykwa; Emilia Sawicka; Maciej Haberka; Małgorzata Setny; Karol Kamiński; Zbigniew Gąsior; Aldona Kubica; Dirk De Bacquer; Guy De Backer; Kornelia Kotseva; David Wood; Andrzej Pająk; Danuta Czarnecka Journal: Cardiol J Date: 2020-05-21 Impact factor: 2.737
Authors: S Störk; P U Heuschmann; K Ungethüm; S Wiedmann; M Wagner; R Leyh; G Ertl; S Frantz; T Geisler; W Karmann; R Prondzinsky; C Herdeg; M Noutsias; T Ludwig; J Käs; B Klocke; J Krapp; D Wood; K Kotseva Journal: Clin Res Cardiol Date: 2022-09-27 Impact factor: 6.138
Authors: Angel M Dzhambov; Penka D Gatseva; Mariya P Tokmakova; Nikolai G Zdravkov; Stefka V Vladeva; Dolina G Gencheva; Nevena G Ivanova; Krasimir I Karastanev; Emanuela V Vasileva; Aleksandar T Donchev Journal: Noise Health Date: 2017 Nov-Dec Impact factor: 0.867
Authors: T M van Schaik; H T Jørstad; T B Twickler; R J G Peters; J P G Tijssen; M L Essink-Bot; M P Fransen Journal: Neth Heart J Date: 2017-07 Impact factor: 2.380
Authors: Marjolein Snaterse; Harald T Jorstad; Marlies Heiligenberg; Gerben Ter Riet; S Matthijs Boekholdt; Wilma Scholte Op Reimer; Ron J Peters Journal: Open Heart Date: 2017-07-11
Authors: Esther de Beus; Nicolette G C van der Sande; Michiel L Bots; Wilko Spiering; Michiel Voskuil; Frank L J Visseren; Peter J Blankestijn Journal: BMJ Open Date: 2017-09-06 Impact factor: 2.692